Addendum

Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90

Status
Status: Commission completed
Project no.
A20-17
Last updated

Report documents

  1. Addendum

    Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90

    published on
    Document type
    PDF document, 225 kB, EN, not accessible

Dossier assessment

Indication:

Patients with solid tumours that display an NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options

Result of dossier assessment:

Conclusion of dossier assessment A19-90 unchanged: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2020-04-02 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-17
Commission
Commission awarded on 25.03.2020 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-90
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form